Physician profile
Sushil Gupta
NPI 1174954960
$4,247.62
in general payments reported to CMS, 2019-2025
24 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $822 · 2021: $967 · 2022: $783 · 2023: $201 · 2024: $311 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777 · Education: $47.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.37 |
| Education | $47.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $681.36 | 2019-2022 | |
| Harmony Biosciences LLC | $581.25 | 2020-2025 | Wakix |
| Merck Sharp & Dohme LLC | $429.64 | 2019-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.07 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $285.11 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $195.48 | 2019-2022 | |
| Mylan Specialty L.P. | $186.59 | 2021-2022 | |
| Lilly USA, LLC | $161.32 | 2024-2025 | Jardiance, Zepbound |
| Vanda Pharmaceuticals INC. | $127.30 | 2019-2021 | |
| Itamar Medical INC | $127.15 | 2022-2025 | Watchpatone |
| Seapearl East, INC | $126.27 | 2024 | |
| Amarin Pharma, INC. | $124.97 | 2019 | |
| Olympus America INC. | $120.29 | 2019 | |
| Philips North America LLC | $118.72 | 2019-2023 | |
| Axsome Therapeutics, INC. | $118.08 | 2023 | Sunosi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $105.04 | 2019 | |
| Fisher & Paykel Healthcare INC | $100.53 | 2025 | Fisher & Paykel Healthcare |
| Eisai INC. | $88.59 | 2020-2022 | |
| Resmed Corp | $66.35 | 2024-2025 | |
| Aytu Biopharma, INC. | $38.21 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $23.85 | 2025 | Lumryz |
| Circassia INC. | $18.75 | 2021 | |
| Genzyme Corporation | $15.47 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushil Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.